{"pmid":32361701,"title":"COVID-19 Rapid Guideline in Kidney Transplant Recipients.","text":["COVID-19 Rapid Guideline in Kidney Transplant Recipients.","in the reports presented about COVID-19, patients receiving kidney transplantation have not been specifically studied and based on national flowchart, this population is classified as highrisk group, thus it is necessary to be aware of the step-by-step treatment approach of these patients. Suspicious cases included patients with a history of dry cough, chills or sore throat accompanying by shortness of breath with or without fever, patients with upper/lower respiratory symptoms with radiological manifestations as single or double-sided multilobular infiltrations on CT scan or plain chest radiography, any one that has a history of close contact with a definite COVID-19 case within the last 14 days, any one with a history of presence in COVID-19 epidemic regions within the last 14 days and patient with pneumonia that despite of proper treatment has an inappropriate clinical response and clinical condition becomes more severe in an unusual way or unexpectedly.","Iran J Kidney Dis","Samavat, Shiva","Nafar, Mohsen","Firozan, Ahmad","Pourrezagholi, Fatemeh","Ahmadpoor, Pedram","Samadian, Fariba","Ziaei, Shadi","Fatemizadeh, Somayeh","Dalili, Nooshin","32361701"],"abstract":["in the reports presented about COVID-19, patients receiving kidney transplantation have not been specifically studied and based on national flowchart, this population is classified as highrisk group, thus it is necessary to be aware of the step-by-step treatment approach of these patients. Suspicious cases included patients with a history of dry cough, chills or sore throat accompanying by shortness of breath with or without fever, patients with upper/lower respiratory symptoms with radiological manifestations as single or double-sided multilobular infiltrations on CT scan or plain chest radiography, any one that has a history of close contact with a definite COVID-19 case within the last 14 days, any one with a history of presence in COVID-19 epidemic regions within the last 14 days and patient with pneumonia that despite of proper treatment has an inappropriate clinical response and clinical condition becomes more severe in an unusual way or unexpectedly."],"journal":"Iran J Kidney Dis","authors":["Samavat, Shiva","Nafar, Mohsen","Firozan, Ahmad","Pourrezagholi, Fatemeh","Ahmadpoor, Pedram","Samadian, Fariba","Ziaei, Shadi","Fatemizadeh, Somayeh","Dalili, Nooshin"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361701","source":"PubMed","week":"202019|May 04 - May 10","topics":["Prevention"],"weight":1,"_version_":1666138495877382146,"score":9.490897,"similar":[{"pmid":32351040,"title":"COVID-19 in kidney transplant recipients.","text":["COVID-19 in kidney transplant recipients.","There is minimal information on COVID-19 in immunocompromised individuals. We have studied 10 patients treated at 12 adult care hospitals. Ten kidney transplant recipients tested positive for SARS-CoV-2 by PCR, and 9 were admitted. The median age was 57 (IQR 47-67), 60% were male, 40% Caucasian, and 30% Black/African American. Median time from transplant to COVID-19 testing was 2822 days (IQR 1272-4592). The most common symptom was fever, followed by cough, myalgia, chills, and fatigue. The most common CXR and CT abnormality was multifocal patchy opacities. 3 patients had no abnormal findings. Leukopenia was seen in 20% of patients, and allograft function was stable in 50% of patients. 9 patients were on tacrolimus and a mycophenolic antimetabolite, and 70% were on prednisone. Hospitalized patients had their antimetabolite agent stopped. All hospitalized patients received hydroxychloroquine (HCQ) and azithromycin. 3 patients died (30%), five (50%) developed acute kidney injury. Kidney transplant recipients infected with COVID-19 should be monitored closely in the setting of lowered immunosuppression. Most individuals required hospitalization and presenting symptoms were similar to those of non-transplant individuals.","Am J Transplant","Nair, Vinay","Jandovitz, Nicholas","Hirsch, Jamie S","Nair, Gayatri","Abate, Mersema","Bhaskaran, Madhu","Grodstein, Elliot","Berlinrut, Ilan","Hirschwerk, David","Cohen, Stuart L","Davidson, Karina W","Dominello, Andrew J","Osorio, Gabrielle A","Richardson, Safiya","Teperman, Lewis W","Molmenti, Ernesto P","32351040"],"abstract":["There is minimal information on COVID-19 in immunocompromised individuals. We have studied 10 patients treated at 12 adult care hospitals. Ten kidney transplant recipients tested positive for SARS-CoV-2 by PCR, and 9 were admitted. The median age was 57 (IQR 47-67), 60% were male, 40% Caucasian, and 30% Black/African American. Median time from transplant to COVID-19 testing was 2822 days (IQR 1272-4592). The most common symptom was fever, followed by cough, myalgia, chills, and fatigue. The most common CXR and CT abnormality was multifocal patchy opacities. 3 patients had no abnormal findings. Leukopenia was seen in 20% of patients, and allograft function was stable in 50% of patients. 9 patients were on tacrolimus and a mycophenolic antimetabolite, and 70% were on prednisone. Hospitalized patients had their antimetabolite agent stopped. All hospitalized patients received hydroxychloroquine (HCQ) and azithromycin. 3 patients died (30%), five (50%) developed acute kidney injury. Kidney transplant recipients infected with COVID-19 should be monitored closely in the setting of lowered immunosuppression. Most individuals required hospitalization and presenting symptoms were similar to those of non-transplant individuals."],"journal":"Am J Transplant","authors":["Nair, Vinay","Jandovitz, Nicholas","Hirsch, Jamie S","Nair, Gayatri","Abate, Mersema","Bhaskaran, Madhu","Grodstein, Elliot","Berlinrut, Ilan","Hirschwerk, David","Cohen, Stuart L","Davidson, Karina W","Dominello, Andrew J","Osorio, Gabrielle A","Richardson, Safiya","Teperman, Lewis W","Molmenti, Ernesto P"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32351040","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/ajt.15967","locations":["Caucasian","myalgia","Leukopenia"],"e_drugs":["Tacrolimus","Azithromycin","Hydroxychloroquine","Prednisone"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495707512832,"score":190.28181},{"pmid":32379903,"title":"Outcome of a patient with refractory Hodgkin's Lymphoma on pembrolizumab, infected with SARS-CoV-2.","text":["Outcome of a patient with refractory Hodgkin's Lymphoma on pembrolizumab, infected with SARS-CoV-2.","A 22-year-old female presented the Emergency Department on the 14(th) March 2020 with a 3 day history of cough, pyrexia, sore throat, chills and rigors. Dyspnoea, myalgia, anosmia did not feature at presentation. The patient had a history of early-stage unfavourable-risk, classical Hodgkin Lymphoma (HL) for which she was diagnosed in May 2017. She underwent two cycles of adriamycin/bleomycin/vinblastine/dacarbazine (ABVD) with escalation to bleomycin/etoposide/adriamycin/cyclophosphamide/vincristine/procarbazine/predniso lone (escBEACOPP) for four cycles due to a suboptimal response on interval positron emission tomography (PET) scan.","Br J Haematol","O'Kelly, Brendan","McGettrick, Padraig","Angelov, Daniel","Fay, Michael P","McGinty, Tara","Cotter, Aoife G","Sheehan, Gerard","Lambert, John S","32379903"],"abstract":["A 22-year-old female presented the Emergency Department on the 14(th) March 2020 with a 3 day history of cough, pyrexia, sore throat, chills and rigors. Dyspnoea, myalgia, anosmia did not feature at presentation. The patient had a history of early-stage unfavourable-risk, classical Hodgkin Lymphoma (HL) for which she was diagnosed in May 2017. She underwent two cycles of adriamycin/bleomycin/vinblastine/dacarbazine (ABVD) with escalation to bleomycin/etoposide/adriamycin/cyclophosphamide/vincristine/procarbazine/predniso lone (escBEACOPP) for four cycles due to a suboptimal response on interval positron emission tomography (PET) scan."],"journal":"Br J Haematol","authors":["O'Kelly, Brendan","McGettrick, Padraig","Angelov, Daniel","Fay, Michael P","McGinty, Tara","Cotter, Aoife G","Sheehan, Gerard","Lambert, John S"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379903","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bjh.16798","keywords":["covid-19","hodgkin lymphoma","sars-cov-2","checkpoint inhibitor","haematological malignancy","pembrolizumab"],"locations":["Dyspnoea","myalgia","Hodgkin","Lymphoma"],"e_drugs":["Vinblastine","Etoposide","pembrolizumab","Doxorubicin","Dacarbazine","Cyclophosphamide","Vincristine","Prednisolone","Bleomycin","Procarbazine"],"topics":["Case Report"],"weight":1,"_version_":1666262687701532672,"score":172.94249},{"pmid":32279418,"title":"Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19).","text":["Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19).","During the novel coronavirus pandemic, organ transplant recipients represent a frail susceptible category due to long-term immunosuppressive therapy. For this reason, clinical manifestations may differ from general population and different treatment approaches may be needed. We present the case of a 36-year-old kidney transplanted woman affected by Senior-Loken syndrome diagnosed with COVID-19 pneumonia after a contact with her positive mother. Initial symptoms were fatigue, dry cough and coryza; she never had fever nor oxygen supplementation. Hydroxychloroquine and lopinavir/ritonavir were started, and the antiviral drug was replaced with darunavir/cobicistat after two days for diarrhea. Immunosuppressant levels were closely monitored, and we observed very high tacrolimus trough levels despite initial dose reduction. The patient was left with steroid therapy alone. The peculiarity of clinical presentation and the management difficulties represent the flagship of our case-report. We stress the need for guidelines in transplant recipients with COVID-19 infection with particular regard to the management of therapy.","Transpl Infect Dis","Bartiromo, Marilu","Borchi, Beatrice","Botta, Annarita","Bagala, Alfredo","Lugli, Gianmarco","Tilli, Marta","Cavallo, Annalisa","Xhaferi, Brunilda","Cutruzzula, Roberta","Vaglio, Augusto","Bresci, Silvia","Larti, Aida","Bartoloni, Alessandro","Cirami, Calogero","32279418"],"abstract":["During the novel coronavirus pandemic, organ transplant recipients represent a frail susceptible category due to long-term immunosuppressive therapy. For this reason, clinical manifestations may differ from general population and different treatment approaches may be needed. We present the case of a 36-year-old kidney transplanted woman affected by Senior-Loken syndrome diagnosed with COVID-19 pneumonia after a contact with her positive mother. Initial symptoms were fatigue, dry cough and coryza; she never had fever nor oxygen supplementation. Hydroxychloroquine and lopinavir/ritonavir were started, and the antiviral drug was replaced with darunavir/cobicistat after two days for diarrhea. Immunosuppressant levels were closely monitored, and we observed very high tacrolimus trough levels despite initial dose reduction. The patient was left with steroid therapy alone. The peculiarity of clinical presentation and the management difficulties represent the flagship of our case-report. We stress the need for guidelines in transplant recipients with COVID-19 infection with particular regard to the management of therapy."],"journal":"Transpl Infect Dis","authors":["Bartiromo, Marilu","Borchi, Beatrice","Botta, Annarita","Bagala, Alfredo","Lugli, Gianmarco","Tilli, Marta","Cavallo, Annalisa","Xhaferi, Brunilda","Cutruzzula, Roberta","Vaglio, Augusto","Bresci, Silvia","Larti, Aida","Bartoloni, Alessandro","Cirami, Calogero"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32279418","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/tid.13286","keywords":["covid-19","drug-drug interaction","kidney transplant"],"e_drugs":["Hydroxychloroquine","Steroids","lopinavir-ritonavir drug combination","Tacrolimus"],"topics":["Case Report"],"weight":1,"_version_":1666138491570880516,"score":169.7484},{"pmid":32354634,"pmcid":"PMC7142691","title":"A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia.","text":["A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia.","The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and are being treated with immunosuppression is unclear. We describe 20 kidney transplant recipients (median age 59 years [inter quartile range 51-64 years], median age of transplant 13 years [9-20 years], baseline eGFR 36.5 [23-47.5]) with SARS-CoV2 induced pneumonia. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/day, all but one was commenced on antiviral therapy and hydroxychloroquine with doses adjusted for kidney function. At baseline, all patients presented fever but only one complained of difficulty in breathing. Half of patients showed chest radiographic evidence of bilateral infiltrates while the other half showed unilateral changes or no infiltrates. During a median follow-up of seven days, 87% experienced a radiological progression and among those 73% required escalation of oxygen therapy. Six patients developed acute kidney injury with one requiring hemodialysis. Six of 12 patients were treated with tocilizumab, a humanized monoclonal antibody to the IL-6 receptor. Overall, five kidney transplant recipients died after a median period of 15 days [15-19] from symptom onset. These preliminary findings describe a rapid clinical deterioration associated with chest radiographic deterioration and escalating oxygen requirement in renal transplant recipients with SARS-Cov2 pneumonia. Thus, in this limited cohort of long-term kidney transplant patients, SARS-CoV-2 induced pneumonia is characterized by high risk of progression and significant mortality.","Kidney Int","Alberici, Federico","Delbarba, Elisa","Manenti, Chiara","Econimo, Laura","Valerio, Francesca","Pola, Alessandra","Maffei, Camilla","Possenti, Stefano","Zambetti, Nicole","Moscato, Marianna","Venturini, Margherita","Affatato, Stefania","Gaggiotti, Mario","Bossini, Nicola","Scolari, Francesco","32354634"],"abstract":["The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and are being treated with immunosuppression is unclear. We describe 20 kidney transplant recipients (median age 59 years [inter quartile range 51-64 years], median age of transplant 13 years [9-20 years], baseline eGFR 36.5 [23-47.5]) with SARS-CoV2 induced pneumonia. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/day, all but one was commenced on antiviral therapy and hydroxychloroquine with doses adjusted for kidney function. At baseline, all patients presented fever but only one complained of difficulty in breathing. Half of patients showed chest radiographic evidence of bilateral infiltrates while the other half showed unilateral changes or no infiltrates. During a median follow-up of seven days, 87% experienced a radiological progression and among those 73% required escalation of oxygen therapy. Six patients developed acute kidney injury with one requiring hemodialysis. Six of 12 patients were treated with tocilizumab, a humanized monoclonal antibody to the IL-6 receptor. Overall, five kidney transplant recipients died after a median period of 15 days [15-19] from symptom onset. These preliminary findings describe a rapid clinical deterioration associated with chest radiographic deterioration and escalating oxygen requirement in renal transplant recipients with SARS-Cov2 pneumonia. Thus, in this limited cohort of long-term kidney transplant patients, SARS-CoV-2 induced pneumonia is characterized by high risk of progression and significant mortality."],"journal":"Kidney Int","authors":["Alberici, Federico","Delbarba, Elisa","Manenti, Chiara","Econimo, Laura","Valerio, Francesca","Pola, Alessandra","Maffei, Camilla","Possenti, Stefano","Zambetti, Nicole","Moscato, Marianna","Venturini, Margherita","Affatato, Stefania","Gaggiotti, Mario","Bossini, Nicola","Scolari, Francesco"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32354634","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.kint.2020.04.002","keywords":["acute kidney injury","inflammation","tocilizumab","transplantation"],"e_drugs":["Hydroxychloroquine","tocilizumab","Methylprednisolone"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495273402368,"score":168.09933},{"pmid":32441574,"title":"A case series describing the epidemiology and clinical characteristics of COVID-19 infection in Jilin Province.","text":["A case series describing the epidemiology and clinical characteristics of COVID-19 infection in Jilin Province.","Since its outbreak in Wuhan, Hubei Province China, 2019-coronavirus infected disease (COVID-19) had been widely spread all over the world, the control of which calls for a better understanding of its epidemiology and clinical characteristics. We included 12 confirmed cases of COVID-19 in First Affiliated Hospital of Jilin University from 23 January 2020 to 11 February 2020, which were retrospectively analyzed for epidemiological, demographic, clinical, laboratory, and radiological features. All the patients were confirmed by nucleic acid detection, the average age of whom was 45.25 years (range, 23-79 years). Most patients had a history of Wuhan traveling or had contact with Wuhan travelers or infected cases. Obvious family cluster was observed. Clinical manifestations included fever (12/12), fatigue (10/12), cough (6/12), sore throat (4/12), headache (3/12), and diarrhea (2/12). Only three out of eight patients had pneumonia manifestation on radiography. Most patients had a normal white blood cell (WBC) count and normal or reduced lymphocyte (LY) count. Pneumonia changes were observed in all the four patients who underwent a chest CT scan. Only one elderly patient developed severe pneumonia, while all the rest were mild disease and had a self-limiting course.","Virulence","Du, Na","Chen, Haiying","Zhang, Qing","Che, Lihe","Lou, Lixin","Li, Xiaohua","Zhang, Kaiyu","Bao, Wanguo","32441574"],"abstract":["Since its outbreak in Wuhan, Hubei Province China, 2019-coronavirus infected disease (COVID-19) had been widely spread all over the world, the control of which calls for a better understanding of its epidemiology and clinical characteristics. We included 12 confirmed cases of COVID-19 in First Affiliated Hospital of Jilin University from 23 January 2020 to 11 February 2020, which were retrospectively analyzed for epidemiological, demographic, clinical, laboratory, and radiological features. All the patients were confirmed by nucleic acid detection, the average age of whom was 45.25 years (range, 23-79 years). Most patients had a history of Wuhan traveling or had contact with Wuhan travelers or infected cases. Obvious family cluster was observed. Clinical manifestations included fever (12/12), fatigue (10/12), cough (6/12), sore throat (4/12), headache (3/12), and diarrhea (2/12). Only three out of eight patients had pneumonia manifestation on radiography. Most patients had a normal white blood cell (WBC) count and normal or reduced lymphocyte (LY) count. Pneumonia changes were observed in all the four patients who underwent a chest CT scan. Only one elderly patient developed severe pneumonia, while all the rest were mild disease and had a self-limiting course."],"journal":"Virulence","authors":["Du, Na","Chen, Haiying","Zhang, Qing","Che, Lihe","Lou, Lixin","Li, Xiaohua","Zhang, Kaiyu","Bao, Wanguo"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441574","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/21505594.2020.1767357","keywords":["covid-19","jilin","sars-cov-2","clinical characteristic","epidemiology","severe acute respiratory syndrome"],"locations":["Wuhan","Hubei","China","Wuhan","Wuhan","Jilin"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1667523504701964288,"score":166.73943}]}